Paper Review Records
全部论文审稿周期
5 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接
156
天
Lymphocyte count polygenicity underlies dimethyl fumarate–associated lymphopenia in multiple sclerosis
作者
Kaarina Kowalec; Ali Manouchehrinia; Elaine Kingwell; Robert Carruthers; Ruth Ann Marrie; Charity Evans; Dalia Rotstein; Annie J Kuan; Wenzhuo Luo; Daniel Luo; Brianne Desrochers; Vilija G Jokubaitis; Jeannette Lechner-Scott; Vicki E Maltby; Kira Groen; Galen EB Wright; Britt I Drögemöller; Sasha Bernatsky; Michael C Levin; Katherine Knox; Abdullah Al Maruf; Michael Zhong; Lars Alfredsson; Jan Hillert; Ingrid Kockum; Tomas Olsson; Pernilla Stridh; Klementy Shchetynsky; Kristy Dever; Julie MacIsaac; Michael S Kobor; Helen Tremlett展开收起
作者单位
1. College of Pharmacy, University of Manitoba, Winnipeg, MB, Canada; Department of Biochemistry & Medical Genetics, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada; Department of Medical Epidemiology & Biostatistics, Karolinska Institutet, Stockholm, Sweden; 2. College of Pharmacy, University of Manitoba, Winnipeg, MB, Canada; Karolinska Neuroimmunology and Multiple Sclerosis Center, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; 3. Department of Primary Care and Population Health, Institute of Epidemiology and Health Care, University College London, London, UK; 4. Department of Medicine, University of British Columbia, Vancouver, BC, Canada; 5. Department of Medicine and Community Health and Epidemiology, Faculty of Medicine, Dalhousie University, Halifax, NS, Canada; Nova Scotia Health, Halifax, NS, Canada; Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada; 6. College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada; 7. Department of Medicine, Division of Neurology, University of Toronto, Toronto, ON, Canada; 8. Faculty of Medicine (Neurology), University of British Columbia, Vancouver, BC, Canada; 9. College of Pharmacy, University of Manitoba, Winnipeg, MB, Canada; 10. Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC, Australia; Department of Neurology, Alfred Health, Melbourne, VIC, Australia; 11. Department of Neurology, John Hunter Hospital, Newcastle, NSW, Australia; School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia; Immune Health Research Program, Hunter Medical Research Institute, Newcastle, NSW, Australia; 12. Immune Health Research Program, Hunter Medical Research Institute, Newcastle, NSW, Australia; 13. Department of Biochemistry & Medical Genetics, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada; Department of Pharmacology and Therapeutics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada; PrairieNeuro Research Centre, Kleysen Institute for Advanced Medicine, Health Sciences Centre and Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada; Children’s Hospital Research Institute of Manitoba, Winnipeg, MB, Canada; 14. Department of Biochemistry & Medical Genetics, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada; Children’s Hospital Research Institute of Manitoba, Winnipeg, MB, Canada; CancerCare Manitoba Research Institute, Winnipeg, MB, Canada; Centre on Aging, Winnipeg, MB, Canada; 15. Department of Medicine, Divisions of Clinical Epidemiology and Rheumatology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada; 16. Office of the Saskatchewan Multiple Sclerosis Research Chair, Department of Medicine, Division of Neurology, College of Medicine, University of Saskatchewan, Saskatchewan, Saskatoon, SK, Canada; Department of Anatomy, Physiology and Pharmacology, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada; 17. Department of Physical Medicine and Rehabilitation, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada; 18. College of Pharmacy, University of Manitoba, Winnipeg, MB, Canada; Children’s Hospital Research Institute of Manitoba, Winnipeg, MB, Canada; Department of Psychiatry, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada; 19. Karolinska Neuroimmunology and Multiple Sclerosis Center, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; 20. Karolinska Neuroimmunology and Multiple Sclerosis Center, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; 21. Karolinska Neuroimmunology and Multiple Sclerosis Center, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden; 22. Edwin SH Leong Centre for Healthy Aging, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; Centre for Molecular Medicine and Therapeutics and Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada; British Columbia Children’s Hospital Research Institute, Vancouver, BC, Canada; 23. Faculty of Medicine (Neurology), University of British Columbia, Vancouver, BC, Canada; The Djavad Mowafaghian Centre for Brain Health, Vancouver, BC, Canada展开收起
174
天
Gynecologic complications of disease-modifying therapy in women with multiple sclerosis
作者
Alexandra Balshi; John P Dempsey; Yanli Zhang-James; Riley Bove展开收起
作者单位
1. Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; 2. Norton College of Medicine, SUNY Upstate Medical University, Syracuse, NY, USA; 3. UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA展开收起
79
天
166
天
Multiple sclerosis outcomes after cancer diagnosis in people with recorded chemotherapy exposure: A real-world MSBase study
作者
Cassie Nesbitt; Paul Sanfilippo; Chao Zhu; Serkan Ozakbas; Alexandre Prat; Marc Girard; Pierre Duquette; Tomas Kalincik; Izanne Roos; Katherine Buzzard; Olga Skibina; Matteo Foschi; Andrea Surcinelli; Jeannette Lechner-Scott; Francesco Patti; Allan G Kermode; Marzena Fabis-Pedrini; William M Carroll; Suzanne Hodgkinson; Francois Grand’Maison; Eva Kubala Havrdova; Pavel Hradilek; Mario Habek; Davide Maimone; Raed Alroughani; Marta Vachova; Vincent van Pesch; Richard Macdonell; Daniele Spitaleri; Samia J Khoury; Oliver Gerlach; Koen de Gans; Pamela McCombe; Anneke Van Der Walt; Helmut Butzkueven; Vilija Jokubaitis展开收起
作者单位
1. Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC Australia; Department of Neurology, Alfred Hospital, Melbourne, VIC, Australia; Department of Neurology, University Hospital Geelong, Geelong, VIC, Australia; 2. Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC, Australia; Department of Neurology, Alfred Hospital, Melbourne, VIC, Australia; 3. Medical Point Hospital, Izmir University of Economics, Izmir, Turkey; Multiple Sclerosis Research Association, Izmir, Turkey; 4. CHUM and Universite de Montreal, Montreal, QC, Canada; 5. Department of Neurology, Neuroimmunology Centre, The Royal Melbourne Hospital, Melbourne, VIC, Australia; Department of Medicine, CORe, The University of Melbourne, Melbourne, VIC, Australia; 6. Department of Neurosciences, Box Hill Hospital, Box Hill, VIC, Australia; Eastern Health Clinical School, Monash University, Box Hill, VIC, Australia; 7. Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC, Australia; Department of Neurology, Alfred Hospital, Melbourne, VIC, Australia; Department of Neurosciences, Box Hill Hospital, Box Hill, VIC, Australia; 8. Santa Maria delle Croci Hospital, AUSL Romagna, Ravenna, Italy; 9. Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy; 10. Hunter Medical Research Institute, The University of Newcastle, Newcastle, NSW, Australia; Hunter New England Health, John Hunter Hospital, New Lambton Heights, NSW, Australia; 11. Department GF Ingrassia Neurosciences, Università degli Studi di Catania, Catania, Italy; Multiple Sclerosis Unit, AOU Policlinico G Rodolico-San Marco, University of Catania, Catania, Italy; 12. Perron Institute for Neurological and Translational Science, Sir Charles Gairdner Hospital, QEIIMC, University of Western Australia, Nedlands, WA, Australia; Personalised Medicine Centre, Health Futures Institute, Murdoch University, Perth, WA, Australia; Institute for Immunology and Infectious Diseases, Murdoch University, Perth, WA, Australia; 13. Perron Institute for Neurological and Translational Science, Sir Charles Gairdner Hospital, QEIIMC, University of Western Australia, Nedlands, WA, Australia; Personalised Medicine Centre, Health Futures Institute, Murdoch University, Murdoch, WA, Australia; 14. Perron Institute for Neurological and Translational Science, Sir Charles Gairdner Hospital, QEIIMC, University of Western Australia, Nedlands, WA, Australia; 15. Department of Neurology, Faculty of Medicine, Liverpool Hospital, UNSW Sydney, Sydney, NSW, Australia; Department of Medicine, Immune Tolerance Laboratory, Ingham Institute, UNSW Sydney, Sydney, NSW, Australia; 16. Neuro Rive-Sud, Greenfield Park, QC, Canada; 17. Department of Neurology, First Faculty of Medicine, Charles University in Prague, Prague, Czechia; 18. Department of Neurology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic; 19. Department of Neurology, Zagreb Medical School, Zagreb, Croatia; 20. Division of Neurology, Garibaldi Hospital, Catania, Italy; 21. Department of Medicine, Division of Neurology, Amiri Hospital, Sharq, Kuwait; 22. Department of Neurology, Hospital Teplice of the Regional Health System, Teplice Hospital, Ústecký, Czechia; 23. Department of Neurology, Cliniques Universitaires, Brussels, Belgium; 24. Austin Hospital, Department of Neurology, Heidelberg, VIC, Australia; 25. Department of Neurology, Azienda Ospedaliera di Rilievo Nazionale e di Alta Specialita San Giuseppe Moscati, Avellino, Italy; 26. Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, AUB, Beirut, Lebanon; Abu-Haidar Neuroscience Institute, American University of Beirut Medical Center, Beirut, Lebanon; 27. Department of Neurology, Academic MS Center Zuyd, Zuyderland Medical Center, Sittard-Geleen, The Netherlands; Department of Neurology, School for Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands; 28. Department of Neurology, Groene Hart Ziekenhuis, Gouda, The Netherlands; 29. Department of Neurology, Royal Brisbane Hospital, Brisbane, OLD, Australia; The University of Queensland, Brisbane, QLD, Australia展开收起
187
天
DNA methylation partially mediates the associations of Mediterranean diet scores with MS onset-risk: Results from the Ausimmune case–control study
作者
Mehari Woldemariam Merid; Alex Eisner; Daniel J Park; Sam Tanner; Ingrid van der Mei; Vicki E Maltby; Bruce V Taylor; Jeannette Lechner-Scott; Rodney J Scott; Sarah M Thomson; Simon A Broadley; Ellen Morwitch; Trevor J Kilpatrick; Anne-Louise Ponsonby; Steve Simpson-Yap; Ausimmune Investigators Group展开收起
作者单位
1. The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia; 2. Department of Epidemiology and Biostatistics, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia; 3. Melbourne Bioinformatics, The University of Melbourne, Parkville, VIC, Australia; 4. Department of Biochemistry and Pharmacology, The University of Melbourne, Parkville, VIC, Australia; 5. Murdoch Children’s Research Institute, The University of Melbourne, Parkville, VIC, Australia; 6. MS Research Flagship, Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia; 7. School of Medicine and Public Health, Newcastle University, Callaghan, NSW, Australia; 8. Hunter Medical Research Institute, Newcastle University, Callaghan, NSW, Australia; 9. Department of Neurology, John Hunter Hospital, New Lambton Heights, NSW, Australia; 10. School of Biomedical Sciences and Pharmacy, Newcastle University, Callaghan, NSW, Australia; 11. School of Medicine and Dentistry, Griffith University, Southport, QLD, Australia; 12. Neuroepidemiology Unit, Melbourne School of Population and Global Health, The University of Melbourne, Carlton, VIC, Australia展开收起
Expert Matching · Case Demo
把投稿要求，转成可验证的期刊方案
说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。
客户询问
我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？
CrushSCI回复
可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。
- 拟题建议
- 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
样本口径2026 年最近 5 篇有效论文样本
平均审稿62 天
中位数65 天